Chip Davis still believes in innovation, but now must balance that with affordability in new role leading the generic association.

The reauthorization of the Generic Drug User Fee Act isn’t going to be as straightforward as the PDUFA process has been for the past two decades. Instead, expect a replay of the first medical device fee renegotiation – with plenty of threats from industry to walk away from the program altogether, likely intended to end up with the best possible deal.

John Castellani will step down at the end of the year as president and CEO of PhRMA after leading the association since September 2010.